The Phase 2 data release is a positive catalyst for the SkinJect® program, but the company's tiny market cap ($10M) and heavy financial obligations from the Pfizer deal ($12M upfront + $15M due in one year) create significant dilution risk. Monitor for FDA decisions on Orphan Drug and Rare Pediatric Disease designations, and for initiation of SKNJCT-005 enrollment.
Price Chart
Executive Summary
Medicus Pharma published the abridged Clinical Study Report for its Phase 2 SkinJect® trial on ClinicalTrials.gov, confirming the 200-mcg dose selection and a favorable safety profile. The company is prioritizing the FDA-authorized SKNJCT-005 registrational study in Gorlin syndrome, targeting an estimated 11,000 U.S. patients and a modeled $1.1B addressable market.
Key Facts
- Abridged CSR for Phase 2 SkinJect® study (SKNJCT-003) posted on ClinicalTrials.gov, showing complete dataset from 90 enrolled patients with no discontinuations.
- 200-mcg dose selected as proposed pivotal dose for future development.
- FDA-authorized SKNJCT-005 registrational Phase 2b study in Gorlin syndrome to enroll up to ~50 patients.
- Company submitted applications for Orphan Drug Designation and Rare Pediatric Disease designation.
- Independent commercial assessment modeled net pricing of ~$25,800 per treatment, $1.1B TAM, and ~$383M peak U.S. revenue (non-risk-adjusted).
- Company has a $10M market cap and a 7-day-old co-development deal with Pfizer requiring $12M upfront and $15M due in one year.
Financial Impact
Non-risk-adjusted peak U.S. revenue estimate of ~$383M for SkinJect® in Gorlin syndrome; modeled net pricing of ~$25,800 per treatment.
Risk Factors
- Company has only $10M market cap but owes $15M to Pfizer within one year, creating severe dilution or financing risk.
- Gorlin syndrome is a niche indication (~11,000 U.S. patients); commercial success depends on high pricing and reimbursement.
- Phase 2 data is now public but does not guarantee Phase 2b success or regulatory approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3359396 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K | $2.51 $2.45 | ▼ −2.39% | ▼ −2.95% | $2.45 (−2.39%) |
Oct 16, 2026 11d ago | 8-K | $2.66 $2.72 | ▲ +2.45% | ▲ +2.11% | $2.45 (−7.72%) |
Oct 16, 2026 11d ago | SC 13G/A | $2.66 $2.72 | ▲ +2.45% | ▲ +2.11% | $2.45 (−7.72%) |
Oct 7, 2026 20d ago | 8-K | $0.1019 $0.0921 | ▼ −9.62% | ▼ −10.22% | $2.45 (+2304.32%) |
Sep 14, 2026 6w ago | 8-K | $0.1593 $0.1521 | ▼ −4.52% | ▼ −4.06% | $2.45 (+1437.98%) |
Sep 11, 2026 6w ago | 8-K | $0.1626 $0.1593 | ▲ +2.03% | ▲ +1.58% | $2.45 (−1406.77%) |
Sep 10, 2026 6w ago | Press Release | $0.1614 $0.1626 | ▲ +0.74% | ▼ −0.11% | $2.45 (+1417.97%) |
Sep 3, 2026 7w ago | 8-K | $0.1705 $0.1720 | ▲ +0.88% | ▲ +1.27% | $2.45 (+1336.95%) |
Jul 16, 2026 14w ago | Press Release | $0.4060 $0.3758 | ▼ −7.44% | ▼ −6.45% | $2.45 (+503.45%) |
May 14, 2026 23w ago | Press Release | $0.3010 $0.2910 | ▲ +3.32% | ▲ +3.26% | $2.45 (−713.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers